ResMed (RMD) Stock Price, Fundamentals & Analysis

What RMD does

ResMed (RMD) is a stock listed on the ASX in the Healthcare sector, specifically in the Medical Instruments & Supplies industry. Headquartered in San Diego, United States, the company employs 11,370 people. ResMed engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.

Key numbers explained

• 31.58 AUD is the current share price, the amount you would pay to buy one share on the market.
• The trailing P/E ratio of 21.3 shows how much investors pay per dollar of the company's last 12 months of earnings; a higher number can mean the market expects faster growth.
• The forward P/E ratio of 16.6 uses expected future earnings, which can make the valuation look lower if growth is anticipated.
• 1.48 USD is the earnings per share for the trailing 12 months, representing the portion of profit allocated to each outstanding share.
• The dividend yield of 1.19% tells you the annual dividend payment as a percentage of the current share price.
• The exDividendDate is 19 aug. 2026, the date after which a buyer is no longer entitled to the next dividend payment.
• 23% is the share of earnings paid out as dividends, indicating that ResMed returns roughly a quarter of its earnings to shareholders.
• Beta of 0.77 suggests the stock has historically been less volatile than the overall market.
• 45.55 mld. AUD is the market capitalization, the total market value of all outstanding shares.
• The 52-week price range of 25,5 – 43,29 shows the lowest and highest prices over the past year.
• -23.4% is the price change over the last 52 weeks, reflecting the decline from one year ago to the current price.
• 5.65 mld. USD is the trailing 12 months revenue, the total sales the company generated.
• 8.6% is the year-over-year revenue growth, showing how much sales have increased compared to the same period a year earlier.
• 26.9% is the profit margin, the percentage of revenue that remains as net income after all expenses.
• 30.9% is the operating margin, showing how much profit the company makes from its core operations before interest and taxes.
• 24.3% is the return on equity, measuring how effectively the company generates profit from shareholders' equity.
• 12.5% is the debt-to-equity ratio, indicating the proportion of debt used relative to shareholders' equity.
• 1.97 is the price-to-book ratio, comparing the market price to the company's book value per share.

What to watch

ResMed operates in the healthcare and medical devices space, where regulatory approvals, product innovation, and global health trends can influence demand. The company's two main segments—Sleep and Breathing Health, and Residential Care Software—depend on adoption of cloud-connected devices and remote monitoring solutions. As a healthcare stock, it may be sensitive to changes in reimbursement policies, currency fluctuations, and competitive dynamics within the medical instruments industry. Investors often compare it with peers such as Cochlear (COH), Fisher & Paykel Healthcare (FPH), and EBOS Group (EBO) to understand sector positioning. The company is part of the ASX 200, which means it is among the largest listed companies on the Australian exchange. Broader market conditions, interest rate movements, and geopolitical factors can also affect its share price.